Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Georgetown University
This is a single arm, open-label pilot study of Cyberknife plus Gemcitabine in 10 patients with locally advanced pancreatic cancer who have not received prior local or systemic therapy for their pancreatic cancer.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven unresectable, non-metastatic pancreatic adenocarcinoma with measurable or evaluable disease and without involvement of the duodenum
Performance Status 0-2
No prior anticancer therapy for pancreatic adenocarcinoma
No prior anticancer therapy of any kind within the last 5 years
Adequate hepatic, bone marrow, and renal function
Life expectance of \> 12 weeks
Women of childbearing potential must have a negative serum pregnancy test
You may not be if
Duodenal involvement of pancreatic cancer
Metastatic cancer
Active severe infection, or known chronic infection with HIV, hepatitis B virus, or hepatitis C virus
Cardiovascular disease including unstable angina, therapy for life-threatening ventricular arrhythmia, myocardial infarction, stroke, or congestive heart failure within the last 6 months
Life-threatening visceral disease or other severe concurrent disease
Pregnant or breastfeeding
Anticipated patient survival under 3 months
Another active malignancy within the past 5 years except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin.
Clareo Health | A Study of Gemcitabine and Cyberknife Radiation Therapy for Pancreatic Cancer
